Triple-negative breast cancer and HR+/HER2- BC

Clinical trials for Triple-negative breast cancer and HR+/HER2- BC explained in plain language.

Never miss a new study

Get alerted when new Triple-negative breast cancer and HR+/HER2- BC trials appear

Sign up with your email to follow new studies for Triple-negative breast cancer and HR+/HER2- BC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug combo shows promise for Tough-to-Treat breast cancer

Disease control Completed

This phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …

Matched conditions: TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC

Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Triple-negative breast cancer and HR+/HER2- BC

Get alerted when new Triple-negative breast cancer and HR+/HER2- BC trials appear

New drug combo shows promise for Tough-to-Treat breast cancer